Stage IV: Clinical Trials

3 trials for Stage IV, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 unknown. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 1, Completed 1, Unknown 1
Phase 11Completed 1

Follow Stage IV: new trials by email Literature Review of Stage IV trials Research Report on Stage IV

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Rigosertib, Nivolumab - Non-small Cell Lung Cancer, Adenocarcinoma
Phase 1 / Phase 2CompletedIcahn School of Medicine at Mount Sinai252020-06-292024-05-09
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
Durvalumab, Carboplatin, Paclitaxel - Non-small Cell Lung Cancer, Stage IV
Phase 2Active not recruitingETOP IBCSG Partners Foundation962019-11-192026-10-05
Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC
oxaliplatin, Cisplatin - Stomach Neoplasm, Stage IV
Phase 2UnknownGachon University Gil Medical Center902007-07-012007-08-01

Narrower conditions

Carcinoma, Non-Small-Cell Lung (2)  ·  Adenocarcinoma (1)  ·  Neoplasm Metastasis (1)  ·  Recurrence (1)  ·  Stomach Neoplasms (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Bronchial Neoplasms (2)  ·  Carcinoma, Bronchogenic (2)  ·  Lung Diseases (2)  ·  Lung Neoplasms (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Thoracic Neoplasms (2)  ·  Carcinoma (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Disease Attributes (1)

Interventions

Carboplatin (1)  ·  Cisplatin (1)  ·  Nivolumab (1)  ·  ON 01910 (1)  ·  Oxaliplatin (1)  ·  Paclitaxel (1)  ·  Radiosurgery (1)  ·  durvalumab (1)  ·  tremelimumab (1)

Sponsors

ETOP IBCSG Partners Foundation (1)  ·  Gachon University Gil Medical Center (1)  ·  Icahn School of Medicine at Mount Sinai (1)

Countries

Italy (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United States (1)

Top investigators

Isabelle Schmitt-Opitz, MD (1)  ·  Matthias Guckenberger, MD-PhD (1)  ·  Rajwanth Veluswamy, MD, MSCR (1)  ·  Se Hoon Park, MD (1)

NIH funding

2018 (1)